试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- Pfizer Inc.
- 入组人数
- 27
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
A Study to Learn About the Taste Profiles of Different Suspensions of Study Medicine Called PF-07923568 in Healthy Adult ParticipantsRSV (respiratory syncytial virus)MedDRA version: 21.1Level: PTClassification code: 10061603Term: Respiratory syncytial virus infection Class: 100000004862CTIS2023-504924-24-00Pfizer Inc.12
进行中（未招募）
1 期
A study investigating the safety, tolerability, absorption, excretion and effects of a new drug for the treatment of epilepsy.EpilepsyCTIS2022-502638-17-00Trevena Inc.24
进行中（未招募）
1 期
A Study to Learn How Different Amounts and Forms of the Study Intervention Called PF-07899895 are Tolerated and Act in the Body of Healthy Adultslcerative ColitisMedDRA version: 20.0Level: PTClassification code: 10009900Term: Colitis ulcerative Class: 100000004856CTIS2023-507354-32-00Pfizer Inc.45
招募中
1 期
A study in healthy subjects investigating the safety, tolerability and concentrations of FE 999301 after single and multiple dosesInflammatory Gastrointestinal DiseaseMedDRA version: 20.0Level: HLGTClassification code: 10017969Term: Gastrointestinal inflammatory conditions Class: 10017947CTIS2023-507882-24-00Ferring Pharmaceuticals A/S48
进行中（未招募）
1 期
A study to learn how PF-07817883 is taken up into the blood of healthy adults after taking tablets of study drug with varying ingredientscoronavirus disease 2019MedDRA version: 23.0Level: LLTClassification code: 10084382Term: Coronavirus disease 2019 Class: 10021881CTIS2023-506442-24-00Pfizer Inc.12